Loading company
Assembly Biosciences, Inc.
ASMB · Nasdaq · ·
Next earnings: November 9, 2026
$23.45-0.7%Sep 29 close
- 1M
- -31.2%
- 6M
- -12.0%
- 1Y
- -8.4%
- 5Y
- -44.2%
ASMB · Nasdaq · ·
Next earnings: November 9, 2026
$23.45-0.7%Sep 29 close
Assembly Biosciences, Inc. is scheduled to report next on November 9, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toMar 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $13.4M | $9.4M | +41.99% |
| Profit | -$3.9M | -$10.2M | +62.18% |
| Profit per share | -$0.20 | -$1.33 | +84.96% |
| Free Cash Flow | -$15.5M | -$16.8M | +7.58% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The first quarter reflected steady progress across our portfolio as we continue advancing our discovery and development programs,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Assembly Biosciences is a biotechnology company dedicated to the development of innovative small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Assembly Biosciences, Inc.’s Item 2.02 8-K filed May 7, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Assembly Biosciences, Inc. has no earnings call transcript available.